Tests a heart mapping device to guide treatment of persistent atrial fibrillation
Tests a mapping device to guide ablation in adults with persistent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Endocardial Mapping With the CoreMap EP Mapping System
Key facts
- Where
- Praha Klanovice, CzechiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06529978, who can take part
Where in Czechia
- Na Homolce HospitalPraha Klanovice, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CoreMap Inc.
- Trial code
- NCT06529978
- Record updated
- 14 July 2026
- Original description
This is a global, multi-site, prospective, feasibility study.Read full original descriptionShow less
Endocardial Mapping With the CoreMap Electrophysiology Mapping System for Persistent Atrial Fibrillation Protocol
This is a global, multi-site, prospective, feasibility study.
Inclusion: Subject has persistent or long-standing persistent AF, at the discretion of the investigator (Phase 1 \& 2); Subject has PerAF with no history of prior AF ablation therapy (Phase 3); Subject is 18 to 80 years of age; Subject has presence of AF-related symptoms and is scheduled for clinically indicated standard of care AF ablation to manage PerAF (Phase 2 or 3) or long-standing PerAF (Phase 2); Subject is able to provide written informed consent; Subject is able and willing to complete all study procedures.
Exclusion: Active drug or alcohol dependency; Any of the following within three months of enrollment:; Myocardial infarction (MI); Any surgical or percutaneous cardiac procedure including coronary intervention and cardiac ablation; Confirmed thrombus on imaging; Any of the following within six months of enrollment:; Cardiac surgery including coronary artery bypass grafting, ventriculotomy, atriotomy; Thromboembolic event (stroke); AF secondary to electrolyte imbalance, acute alcohol intoxication, or reversible or non-cardiac cause; Severe pulmonary disease, pulmonary hypertension, or any chronic respiratory condition; Renal failure requiring dialysis or transplant; Acute illness, active systemic infection, or sepsis; Hypertrophic cardiomyopathy or cardiac amyloidosis; Any of the following cardiac conditions:; New York Heart Association (NYHA) IV; Left ventricular ejection fraction (LVEF) < 30%; Left atrial diameter >55mm (anterioposterior) (Phase 3); Carotid stenting or endarterectomy; Atrial or ventricular septal closure or left atrial appendage closure; Implanted permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator; loop recorders are permitted; Presence of intramural thrombus, tumor (including atrial myxoma), or other abnormality that precludes vascular access, catheter introduction, or manipulation; Unstable angina; Prior mitral or tricuspid valve surgery, repair, prosthetic or mechanical valve; Moderate to severe mitral valve stenosis or other severe valvular disease; Any blood clotting or bleeding abnormalities; Contraindication to systemic anticoagulation; Body mass index (BMI) > 40 kg/m2; Cor pulmonale; Any contra-indication that may extend procedure time, at the discretion of the operator; Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence; Subject considered part of vulnerable population; Life expectancy less than one year; Employee of the study site or Sponsor; Subjects who are currently enrolled in another study that would directly interfere with this study.